Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.

What It Covers

The paper reports a study of Semaglutide and Glucagon, published as a meta-analysis.

This systematic review and meta-analysis evaluated the effects of oral semaglutide, compared with placebo, on cardiometabolic risk factors in overweight and obese adults with or without diabetes.

Who the Included Studies Covered

The treatment and control groups received oral semaglutide and placebo, respectively.

The researchers pooled data using a random-effects model to estimate changes in outcomes by reporting Estimated Treatment Difference (ETD) as mean difference.

How the Review Was Done

In this systematic review and meta-analysis, following PRISMA 2020 guidelines, PubMed, Embase, and Scopus were searched through 25 August 2025.

Randomized controlled trials (RCT) with overweight and obese populations, with or without diabetes, were included.

Outcomes were cardiometabolic factors and adverse events at baseline and follow-up.

What Was Measured

This systematic review and meta-analysis evaluated the effects of oral semaglutide, compared with placebo, on cardiometabolic risk factors in overweight and obese adults with or without diabetes.

The subject headings attached to it are Semaglutide, Glucagon-Like Peptides, Obesity, Overweight, Cardiometabolic Risk Factors, Diabetes Mellitus and Hypoglycemic Agents.

The authors tagged it with the keywords Body weight, Meta-analysis and Systematic review.

What This Means in Plain Language

This is a meta-analysis of Semaglutide and Glucagon.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (BMC pharmacology & toxicology), a journal based in England.

More context: the Semaglutide compound page and the Glucagon compound page, all human trials.